Member Info for Nael

My assumption is they will raise an additional tranche of development finance without a dilutive rights issue that would offer common shares at a discount.

At best a hold. The price chart looks terrible: flat to declining net money flow. Without an approved confirmed product for sale its a " dead duck " IMHO

These look like low volume bot- drive trades? Anyone have some insights on this issue?

I agree in that I have lost faith in our IC small-cap analyst: stocks are ( often) suggested as buys often when the technical indicators show prices declining against the moving averages and/ or with evident distribution. RBGP is oversold but now faces resistance.

I think they're buys, some institutional or HNW individual buying in

The stock has seen net accumulation over the last 7 weeks with some significant volume spikes indicating ( IMHO), the inflow of some well- informed investors. I am content to initiate an initial position below the price at which the CFO purchased >£22k of shares in 23rd June. I'll accumulate up to a £10k position with a trailing stop loss. Enabling the development of Precision Medicine is an important theme linked to the increased personalisation of oncology treatments. I have an Oncology background and work in the NHS , so I can claim to have some insights in this niche area. Diaceutics is " under the radar" of most investors. Let's hope that the old adage of : " from small acorns grow great oak trees" applies here over time!

There was nothing unusual about the future anticipated development funding required through to 2026 needed to progress the four lead therapeutic candidates. If the outcome from the phase 1 study including assurance provided from the dose escalation then there should not be a problem in raising debt finance as opposed to a share dilution. The board have been transparent in this regard. IMO there is nothing astray

You make a good point. There are so many bot driven trades of insignificant value which blur the true picture. The cumulative accumulation / distribution over a 14 day period is one of a few technical indicators that I follow.

If you register withi the ( Investor Meet Portal) you should be able to view today's presentation. It would appear that the phase 1 study for OCTP's lead candidate is on track and the dose escalation study was clearly explained. The unique indication for chemotherapy induced neuropathy is an exciting area in which to be developing a novel therapeutic that would not possess the toxicity profile of current pain medications that might be prescribed in such a scenario. The second agent under development indicated for trigeminal neuralgia delivered via an inhaler will be proposed for phase 1 next.

The others were covered and an explanation provided to the in-licensing model for a larger collection of potential drug candidates.

The answers around funding were addressed honestly and the management team has integrity in my opinion.

I have a certain amount at risk through stop loss placement on my 4 trades to date and am personally comfortable in investing at an early stage with an expectation of 3-5x at least.

The newsflow over the next 6 months will be critical as the share price moves quickly on news. IMO , OCTP is currently undervalued.

I topped up at 1.06 & 1.078 but the latter just under 1m shares is not yet posted. IMO, market markers are intentionally holding back the offer price. You can see the Doji candlestick patterns on several days on the daily price chart. I am here for the long term !

I undertook my own due diligence having seen mention of a supposed placing between 0.6- 0.7p

This appeared on the ADVFN bulletin board.

It is complete nonsense.

I asked Clarissa as CEO the question , directly.

The share price has drifted back on low volume since the MHRA approval announcement and I have noted buy signals intraday on the candlestick chart when the bid drops , shares are hoovered up. I for one am here for the long-term. P.I.s on AIM are generally a fickle crowd.

I am confident in the prospects for OCTP.

DYOR and assess whether anything has fundamentally changed when the price drops.

Best Wishes to all LT Holders hoping to multi- bag on their investment in OCTP. If the phase 1 study is positive with the lead drug candidate I would expect the bid price to be between 2-3p by year end.

Impatience and panic has kicked in today. My stop losses got hit on the majority of my holding , which I always use to control risk so I never am at risk of > 1% total portfolio value on any one trae after some prior hard lessons.

To observe since the low of 2017, £88m of net inflows to date suggests accumulation by serious investors.

Typographical error in my prior post: should read as " Market Makers"

I agree that : frustration amongst impatient private investors has caused the fall from the move up on the morning of the confirmation of MHRA approval for the phase 1 clinical study. Subject to the initial findings and progression to stage 2/3 we should see more consistent price action.

Nothing has fundamentally changed regarding the outlook for this early stage company that may introduce a game- changing medication , yet the market makets have adjusted the ask price by >30%

I keep my stop way below it can be " picked off" at obvious levels of support in what's referred to commonly as a " tree- shake" by MMs.

DYOR , speak to oncologists if you know any/ hospital pharmacists who sit on drug formulary groups , as I have done ( as I work within the NHS and hold, accumulate or sell- your choice).

I hope for a 3-10x within 2 years.

N

It was a buy but recorded as a sell, that's what's strange

My 15,000 initial purchase at 41.56p via HL recorded as a sale! I read an analyst report online and noted an uptick in ositive money flow very recently. 11% stop- loss, so worth speculation IMO

I think I,ll hold my modest original 40,000 shares with the hope the company recovers in time. I don't want to sell out at a silly price during the auction. HL have not been helpful in their communication IMHO. It appears that a Crest transfer to the Asset Match platform is suggested irrespective of whether the shareholder wishes to sell or not. Please post links if anyone has useful information that will help us collectively. The previous management should step away, they failed us as shareholders, shame on those ( dogs).

The 14 day money flow as measured by the accumulation/ distribution technical indicator is uptrending , suggestion a steady accumulation. I've added another 5,000 shares a small purchase, showing as a sell as its to the left of the mid point of the current bid- offer spread on the trades for today ( one so far), but it's a buy. An illiquid stock which is 1% of my overall portfolio. A punt on overseas property development with a significant dividend . Stop set at 11% below bid pricing of my entry points.

After studying the original prospectus and value proposition for the technology, I've initiated a long position of 330,000 shares, not yet showing . I intend to keep this as a core ISA holding. PYC may get acquired within the next 2-3 yrs IMO.

Thanks for a useful summary of the options open to us as private investors. I will hold with the expectation that the value of Veative will increase. There is no point in selling at 2p/ share IMO as I would personally crystallise a £10k loss by doing so.